Publication | Open Access

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Second-line TreatmentPlacebo-controlled Phase 2OncologyGastrointestinal OncologyMedicinePathologyColorectal CancerImmune Checkpoint InhibitorCancer TreatmentPharmacologyRadiation OncologyMolecular Oncology